In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reed Miller

Deputy Editor

Washington, DC
Reed, deputy editor for commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. His primary focus has been clinical trials and new product development, so he has covered innumerable FDA advisory panel meetings and Medicare coverage decisions. Mixed in to his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for, when it was the best news source for cardiologists. In 2015, he’s became deputy editor of Clinica, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.

Latest From Reed Miller

Interview: New Biotronik CMO David Hayes Builds Physician Education, Clinical Trial Relationships

In an interview with Medtech Insight, Biotronik president Ryan Walters explained why the former Mayo Clinic cardiologist was the right choice to be the first CMO in the company's history and David Hayes discussed his reasons for taking the job.

Exec Chat Commercial

Device Week, 17 May 2020 – COVID-19 Impact On Q1 2020 Earnings In Orthopedics; Highlights From HRS 2020

In this week’s podcast, Medtech Insight's Reed Miller highlights trial results from Boston Scientific and Medtronic at HRS 2020, and Marion Webb discusses the impact of COVID-19 on Q1 2020 earnings results of major orthopedics companies.

Device Week Coronavirus COVID-19

HRS 2020: Boston Scientific’s Next-Gen LAAC Device Hits Targets In PINNACLE FLX Trial

The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.

Clinical Trials Innovation

HRS 2020: Medtronic’s Pacemaker Monitoring App Proves Reliable In BlueSync Study

The BlueSync Evaluation study showed pacemaker patients using the MyCareLink Heart mobile device app were able to stick to their prescribed transmission schedule more often than patients using beside consoles.

Clinical Trials Telehealth

HRS 2020: New Trial Data Support Medtronic’s Micra Pacemaker

The Micra CED study showed a lower rate of complications with the Micra leadless pacemaker than transvenous single-chamber pacemakers.

Clinical Trials Innovation

HRS 2020: Boston Scientific’s Emblem S-ICD Proves Safe And Effective In ‘Sickest Population’

Results of two studies presented at the Heart Rhythm Society Scientific Sessions support the subcutaneous implantable cardioverter defibrillator as an alternative to ICDs with transvenous leads.

Clinical Trials Innovation
See All